Therapeutic Immunity with Multiple Modes of Attack

Chemically programmable immunity is an underutilized tool that can be powerful in thwarting pervasive diseases. Targeted vaccines that activate multiple immune responses are necessary to eradicate the most persistent infectious diseases.

The immune system is complex and robust. Different characters play distinct roles in order to provide communication within the system, as well as signal for attacks and retreats. Since the immune system can be so powerful, a series of checkpoints are set into place in order to tell the immune system which cells are healthy and don't need to be attacked. However, these checkpoints can be hijacked by cancer cells, causing them to be mistakenly recognized as on the same team of the immune system. Pervasive diseases incorporate multiple tools in order to evade the immune system and wreak havoc.

VERAPTUS® therapeutic aptamers fight back against cancer, viruses, and bacterial diseases by providing treatment that effectively stimulates and guides the immune system while also inhibiting unwarranted checkpoints in order to efficiently remove perpetrators throughout the body.

Urgent Need for More Effective Therapy

Due to decades of antibiotic usage, infectious diseases have evolved to become highly resistant to even the most powerful antibiotics available. Bacterial infections are an incredible burden to humanity and society. VERAPTUS® therapeutic aptamers will mitigate this problem across the globe. In addition to bacteria and cancer, VERAPTUS® therapeutic aptamers target viruses that pose public threats. Infectious diseases account for the second most frequent cause of death globally. The WHO estimates 16.2% of all deaths globally can be attributed to infectious diseases.

Immediate Immunity Against Bacterial and Viral Diseases

Traditional vaccination is not best suited in instances of outbreaks due to the amount of time for the body to develop immunity towards the virus or disease. VERAPTUS® therapeutic aptamers are particularly beneficial during such outbreaks.

VERAPTUS® therapeutic aptamers not only are able to ablate the most stubborn forms of bacterial and viral infections but also allow for a variable that can evolve as biology does. The human body is remarkable at attacking foreign agents that enter our bloodstream but sometimes our immune system needs a helping hand. Optimizing this platform in order to seek out destabilizing pathogens that successfully subvert the immune system while turning these pathogens into targets, signals the immune system to initiate multiple mechanisms of attack.

Targets: MRSA, MDR-TB, and Cancer

Methicillin-resistant Staphylococcus Aureus (MRSA)

MRSA has reached epidemic status in many parts of the world. Current treatment for MRSA is becoming even more problematic as resistance develops against even the strongest antibiotics currently on the market.

MRSA not only poses a threat to health but also creates an incredible economic burden. In the U.S. alone, MRSA accounts for a healthcare cost of approximately $34 billion a year. As for mortality, recent estimates in the U.S. indicate mortality due to MRSA infections is even higher than that resulting from HIV/AIDS.

1 out of 3 people can be carriers of Staphylococcus Aureus while it lives on their skin or in their nose.

Multidrug-resistant Tuberculosis (MDR-TB)

This ancient bacteria continues to take the lives of many each year. TB tends to stay in a latent stage for an unpredictable amount of time prior to entering the active state, making it difficult to diagnose or treat the disease.

A staggering number of TB cases are being identified as MDR-TB, making treatment especially difficult. The reported cases of MDR-TB and TB indicate that MDR-TB is growing proportionally to the total. In 2012, out of 12 million globally reported cases of TB, 650,000 were confirmed to be MDR-TB.

VERAPTUS® therapeutic aptamers will effectively manage this harmful bacteria. Currently, controlling MDR-TB is an emotional burden for patients with courses of treatment, employing up to six different second-line drugs, lasting up to 24 months.


Cancer cells are notorious for their ability to evade the immune system. Their ability to stay "cloaked" from the sight of the soldiers of the immune system allows them to go relatively unchecked.

Clinical research has shown that cancer takes advantage of the immune system's checkpoints. Cancer's signals trick the immune system into believing that an offensive attack is not needed. VERAPTUS® therapeutic aptamers inhibit these checkpoints, allowing for a duration of unimpeded offensive attacks against the cancer cells.

Immunotherapy is making great inroads in the fight against cancer, where chemotherapy and radiation have had limited success. VERAPTUS® therapeutic aptamers are at the forefront of this powerful weapon against cancer.